I used to do that but would recommend building a position over a period of months. I started buying when SYN was 1.01 and have played the swing trades. I built back a position now 89K shares, added 4K today at 1.41-.43 and have my average price now at $1.545. Your conviction happened all at once, mine has built over time, and today was a good day, closing up to the 1.49 after I had added this morning. Good luck all, this is going to be an exciting ride. Knowing I'm in with the famous J. Randall Kirk, and Michael S. Dell's Fund makes for added confidence. I think Riley is outstanding, love to listen to him report.
Five patents issued, exclusivity out to 2022, 325 sales reps covering territory, $400M total potential market. Sales to commence next month, accretive $45 million acquisition.
You must have missed the poster presentations at the recent conferences which documented the effectiveness of the platforms IDRA is advancing. Your parallel isn't.
You are jaded, you shouldn't post with your attitude as a long, your negativity helps bashers, and you show your sentiment as 'Buy', ask yourself who, after reading your post, wants to own what you say is a Buy? Just sell your stock if you don't have confidence in your investment or CEO. Don't stay here and complain.
Currently even on the day at 1.14. Since 1993, I would imagine if you've followed the stock that long, you have been in and out of it, profits and losses both. Where do you see this end of 2015?
We don't sell off anymore into these weak market days. You can invest your money and have confidence your money isn't going to be blown around like straw in a storm. It's a new phenomena with IGXT, since we have been transformed into a 'soon to be profitable' company with growing revenues.
From my look around on the charts today, dropping oil prices and world indexes brought our stock down 2 cents, but it was down at much as .07 at the day's low. We have had a downdraft in line with the market, our close on December 1st was 1.66 and today 1.45. We have fared better than many stocks, but we have dropped a $0.21 since December 1st when we closed at $1.66. That is 12.65%. Not fun, we are a micro cap developmental biotech stock, so not surprising. Am I happy with this? No. You can sell and take a year-end loss or break even, there are people doing that. They will never see the enormous upside of this stock, because they will join the thousands who leave their money on the table every day and don't come back. Timing, patience. We know we can be right the idea, but wrong the timing. Michael S. Dell is early invested here with his Fund. He isn't selling, nor are insiders like J. Randall Kirk, founder of SYN and XON. Who controls the timing? We do, psychological thing called fear leads us to sell at the wrong time. Do I know it's going to turn around and go up soon? No, but that is my bet, what's your bet?
Tina, how can you stay so positive, in the midst of your affliction and this market? I love your attitude and it inspired me today, so thank you!
STEM tanked nearly 11% versus our 7.36%. What's to keep them from dropping into the next months awaiting a decision? People with enough guts to catch a falling knife I suppose, it's too bad, this has really hurt a lot of shareholders, the overhang of this suit.
This was an excerpt from an article in 2012 that was put out through the AP.
"About 600,000 knee replacement surgeries are done each year nationwide on adults of all ages, costing a total of $9 billion, the authors said. A journal editorial says measures are needed to control costs of these operations, noting that demand has been projected to rise to as many as almost 4 million knee operations annually by 2030."
Is anyone familiar with whether Pennsaid would be among those medicines that would be prescribed for knee replacement patients, after their operation has healed? Would be a huge market if so.
October 17, 2014 08:00 AM Eastern Daylight Time
COLUMBIA, Md.--(BUSINESS WIRE)--Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today that it has entered into an exclusive commercial and development partnership for its cartilage product, Cartiform, with Arthrex, Inc. Arthrex is a global medical device company and the leader in new product development and medical education in orthopaedics and sports medicine, operating in over 90 countries throughout the world.
“Arthrex is excited for the opportunity to partner with Osiris on the commercialization of the Cartiform technology. Arthrex has the product development and distribution capabilities to train and educate surgeons about the unique characteristics of Cartiform and to help them better treat their patients”
"We are excited to enter this strategic partnership with Arthrex, the clear industry leader in sports medicine, as well as in foot and ankle devices and instrumentation, to address an unmet need in cartilage repair that demands an innovative cellular regenerative medical solution," said Dwayne Montgomery, Osiris’ General Manager of Orthopaedics and Sports Medicine. Cartiform, a viable chondral allograft, offers a unique solution to repair and restore damaged cartilage in the knee, foot, ankle, and other major joints. Cartiform has demonstrated promising clinical outcomes.
The cartilage repair market represents a significant opportunity, with up to 500,000 patients needing treatment in the U.S. per year. Cartilage has limited ability to self-repair and the current standard of care, microfracture or bone marrow stimulation, remains unsatisfactory. Cartiform combines distinct clinical advantages of fresh stored allograft with the logistical and delivery advantages of non-viable, point of care implants.
Wow, I'll say, today you could have bought as low as 1.41 if you had a standing order in, but otherwise, 1.43-1.44 was very cheap for this forward equity value. My last buy was at 1.47 and I didn't buy today, that was last week. Good things in very short order for our stock.
Huge swings, got that right, repeat performance maybe. AH today traded up .14. Let's look for a recovery between now and end of year. Or, the January effect if there is no December relief. Good luck longs.
And that was Friday, but your title line is still correct, only CUR had the additional 7% drop today. I sold most of mine at 2.81, and 2.73. They are tossing biotech under the bus. I hold HZNP and IGXT, one up, one even. IDRA was biggest of my down stocks today.
We hope it won't last, watching to see when volume comes in. Good luck with your position MGM.
Investors should look at the anxiety calming drug RIZAPORT(TM) being developed by Intelgenx IGXT, which uses their patented VERSAFILM technology. IGXT is going to be profitable in 2015, shares now trading at .59, easy double from here and likely much higher for patient investors. Company will likely be sold around $5.00, diverse pipeline. When approved it will grab huge market share based on the rapid uptake, and faster action than current standard of care.
This morning there are 2,000 shares offered at .59 and there are 11,200 shares on the bid at .58, which is reflective of how it's going to be difficult to accumulate shares without pushing the price up. Holders know they have a gold mine going forward and refuse to let go of their shares. It is so thinly traded, anyone short in here is going to face difficulties covering without causing price to go up.
Don't overlook the likelihood of a partnership announcement soon to follow the news of an approval. This second catalyst will complicate the decision by 'traders' to sell the news, because the partnership likely will bring with it an up front payment and a buoyant stock price as investors look further ahead to the revenue picture which surely will be coming into focus upon approval. Investors who sell the news could miss upside from this, so be careful of listening to those who would have you believe approval is priced in.